Brief: SAB Biotherapeutics Diversitab Platform Proves To Develop Anti-Idiotype Antibodies
05/01/2023 13:59
Jan 5 (Reuters) - CSL Ltd CSL.AX :
* SAB BIOTHERAPEUTICS NOVEL DIVERSITAB™ PLATFORM PROVEN TO
DEVELOP
ANTI-IDIOTYPE ANTIBODIES TO HELP TREAT AUTOIMMUNE DISEASES
Source text for Eikon: ID:nGNX74jMVv
Further company coverage: CSL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies